Evidence map›Paper›PMID 19800989›Full record

ArticleNanomedicine : nanotechnology, biology, and medicine2010

Ligand-modified gene carriers increased uptake in target cells but reduced DNA release and transfection efficiency.

Yen Cu, Cathy LeMoëllic, Michael J Caplan, W Mark Saltzman

Abstract read
In one paragraph

Article in Nanomedicine : nanotechnology, biology, and medicine, 2010. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 14 papers.

0numbers the graph read from it
0cells of the map it votes in
14citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

14 citing papers in PubMed.

  1. Article
  2. Article
  3. Review
  4. Article
  5. Article
  6. Article
  7. Review
  8. Article
  9. Surface modified poly(β amino ester)-containing nanoparticles for plasmid DNA delivery.Journal of controlled release : official journal of the Controlled Release Society · 2012
    Article
  10. Article
  11. Article
  12. Enhancement of surface ligand display on PLGA nanoparticles with amphiphilic ligand conjugates.Journal of controlled release : official journal of the Controlled Release Society · 2011
    Article
  13. Article
  14. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors.

Yen CuDepartment of Biomedical Engineering, Yale University, New Haven, Connecticut 06511, USA.
Cathy LeMoëllic
Michael J Caplan
W Mark Saltzman

Funding

Molecular and Cellular Transport in MucusR01EB000487 · NIBIB · YALE UNIVERSITY · PI IWASAKI, AKIKO, SALTZMAN, W. MARK · 2002 to 2019
$5.0M
Molecular and Cellular Transport in MucusR56EB000487 · NIBIB · YALE UNIVERSITY · PI SALTZMAN, W. MARK · 2008 to 2008
$402k
NIBIB NIH HHS EB000487NIBIB NIH HHS R01 EB000487NIBIB NIH HHS R56 EB000487
6 · The paper itself

Abstract

DNA delivery to cells can be improved by using particle carriers made from biodegradable polymers such as poly(lactic-co-glycolic)acid (PLGA). It is speculated that addition of targeting moieties to the particle surface to facilitate uptake can further enhance gene expression in specific cells or tissues. Taking advantage of well-known receptor/ligand interactions in intestinal and renal epithelial cells, we formulated PLGA particles with high density of surface-bound bovine serum albumin (BSA; approximately 768 molecules/particle). BSA-coated particles exhibited significantly higher uptake by cells expressing the albumin receptor, megalin, and resisted degradation in low pH. However, gene expression from BSA-coated particles was 3- to 10-fold lower than that from unmodified particles; this reduction in transfection efficiency was probably due to the slower DNA release rate from modified particles. In this setting, addition of a targeting feature to particles reduced their effectiveness. Our study highlights the importance of the interplay between cell uptake and payload release in the design of polymer drug carriers. FROM THE CLINICAL EDITOR: DNA delivery to cells can be improved by using particle carriers such as PLGA. Taking advantage of known receptor/ligand interactions in intestinal and renal epithelial cells, PLGA particles with high density surface-bound BSA were formulated. BSA-coated particles exhibited significantly higher uptake; however, gene expression was 3 to 10-fold lower. Unexpectedly, the addition of a targeting feature to these particles reduced their overall effectiveness.

Indexed as

AnimalsCells, CulturedDNADrug CarriersKidneyLigandsOpossumsTransfectionDNADrug CarriersLigands

Identifiers

PMID19800989
PMCPMC2847641

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.